Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) has provided an update.
ImpediMed Limited has lodged a new prospectus with the Australian Securities and Investments Commission to support an equity raising, centred on a Share Purchase Plan for eligible shareholders. The plan offers up to 200 million new shares at the lower of $0.01 or a 2.5% discount to the five-day VWAP, aiming to raise about $2 million and providing existing investors an opportunity to increase their exposure at a discounted price.
Alongside the Share Purchase Plan, the company is issuing attaching options on a one-for-one basis to participants in the placement, SPP and any shortfall investors, exercisable at $0.01 by March 2027, plus follow-on options for each exercised attaching option at $0.015 by December 2027. This layered options structure is designed to incentivise continued shareholder support and potentially supply additional growth capital over the next two years without immediately diluting the share base further.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian medical technology company listed on the ASX that develops and commercialises bioimpedance-based devices for clinical use. Its products are primarily used in healthcare settings to assess and monitor conditions such as fluid status and lymphedema, targeting hospitals and specialist clinics seeking quantitative diagnostic support.
YTD Price Performance: -58.82%
Average Trading Volume: 4,907,406
Technical Sentiment Signal: Sell
Current Market Cap: A$28.54M
See more insights into IPD stock on TipRanks’ Stock Analysis page.